Chimera Research subscribers can read a preview of the important clinical data from ARRY, and in particular in MEK inhibitors, that will be presented at ASCO in June 2012.
Keep reading for a couple of interesting AACR abstracts related to one of Array's MEK inhibitors - selumetinib aka AZD6244.